Screener
UroGen Pharma URGN Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Jelmyto | $22.03M-9.0% | $21.71M+7.2% | $23.82M-3.0% | $25.7M+2.0% | $24.22M+10.8% | |
| Zusduri | $50.43M— | $29.25M— | $14.02M— | $1.78M— | $0— |
FAQ
- How does UroGen Pharma break its business down?
- UroGen Pharma (URGN) reports revenue by product across 2 parts — Jelmyto and Zusduri. Each is extracted from the segment footnotes and tracked over time.
- Where does UroGen Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in UroGen Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
